1.
The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?
2.
3.
4.
5.
6.
7.
8.
9.
Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
Biosimilars in Belgium: a proposal for a more competitive market
Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD).
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking